Cathleen N Cabansag, MD
Gastroenterology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
- Since medical school
- 22 years
- Loma Linda University School of Medicine, 2004
Offices
1 location · Genesis Healthcare Partners PC · 232 clinicians in this group
Hospitals listed: California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cabansag’s office at (415) 749-6900 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A95509 · Current
Licensed to practise in California · since 2006 · expires 2027-12-31 · Loma Linda University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Gastroenterology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$45,011
Medicare paid this office $45,011 for 161 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 28 | $5,918 | $211 |
| Short return visit (20+ min) | 41 | $4,653 | $80 |
| Biopsy of large bowel using a flexible endoscope | 41 | $4,612 | $112 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 12 | $4,551 | $46 |
| Return visit (30+ min) | 30 | $3,899 | $103 |
See all 11 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 28 | $5,918 | $211 |
| Short return visit (20+ min) | 41 | $4,653 | $80 |
| Biopsy of large bowel using a flexible endoscope | 41 | $4,612 | $112 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 12 | $4,551 | $46 |
| Return visit (30+ min) | 30 | $3,899 | $103 |
| New patient visit (45+ min) | 27 | $3,696 | $137 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 12 | $3,548 | $58 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 16 | $3,104 | $194 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 24 | $2,292 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,290 | $153 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 11 | $2,131 | $194 |
Procedures Medicare counted
| Colonoscopy | 55 | More than 66% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 36 | More than 59% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of large bowel using a flexible endoscope | 36 | 31 | 41 | 41 | 34 | 41 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 44 | 21 | 43 | 36 | 30 | 25 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | – | – | 17 | 13 | 18 | 28 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
161 Original Medicare patients in 2024. Average age 74 · Women 75% · Also on Medicaid 16% · Health risk score 1.15. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 57% · Diabetes 24% · Coronary heart disease 22% · Depression 22% · Chronic kidney disease 14% · COPD 13% · Atrial fibrillation 13% · Heart failure 10% · Cancer 10%.
The office billed $262,840, Medicare allowed $58,300 and paid $45,011; for 460 services of 24 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 161 | 460 | 74 | 1.15 | $262,840 | $45,011 |
| 2023 | 145 | 268 | 74 | 1.00 | $191,799 | $35,040 |
| 2022 | 159 | 302 | 74 | 1.23 | $149,068 | $35,690 |
| 2021 | 160 | 357 | 74 | 1.58 | $150,873 | $49,809 |
| 2020 | 123 | 231 | 73 | 1.23 | $76,210 | $23,914 |
| 2019 | 163 | 362 | 76 | 1.28 | $99,907 | $38,429 |
| 2018 | 179 | 378 | 75 | 1.45 | $109,592 | $42,969 |
| 2017 | 193 | 458 | 74 | 1.64 | $128,234 | $50,408 |
| 2016 | 188 | 418 | 75 | 1.57 | $102,792 | $47,262 |
| 2015 | 141 | 349 | 74 | 1.41 | $116,189 | $40,343 |
| 2014 | 152 | 369 | 73 | 1.35 | $140,520 | $45,210 |
| 2013 | 129 | 296 | 73 | 1.74 | $102,605 | $38,440 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Short return visit (20+ min) | 46 | $4,302 | $80 |
| Return visit (30+ min) | 26 | $4,105 | $108 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 18 | $3,974 | $221 |
| Biopsy of large bowel using a flexible endoscope | 34 | $3,912 | $115 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 18 | $3,651 | $203 |
| New patient visit (45+ min) | 19 | $2,864 | $151 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 29 | $2,578 | $86 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,233 | $186 |
| New patient visit (30+ min) | 14 | $1,249 | $89 |
2022: 7 services
| Biopsy of large bowel using a flexible endoscope | 39 | $5,636 | $137 |
| Short return visit (20+ min) | 63 | $5,548 | $63 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 35 | $3,407 | $95 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 16 | $2,885 | $180 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 12 | $2,884 | $222 |
| New patient visit (30+ min) | 35 | $2,820 | $81 |
| New patient visit (15+ min) | 15 | $621 | $41 |
2021: 8 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $6,801 | $179 |
| Short return visit (20+ min) | 61 | $6,330 | $81 |
| Biopsy of large bowel using a flexible endoscope | 41 | $5,275 | $129 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 40 | $3,945 | $92 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 17 | $3,903 | $230 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $3,047 | $92 |
| New patient visit (30+ min) | 24 | $2,213 | $92 |
| New patient visit (15+ min) | 11 | $629 | $57 |
2020: 6 services
| Short return visit (20+ min) | 49 | $4,872 | $65 |
| Biopsy of large bowel using a flexible endoscope | 31 | $4,825 | $156 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,586 | $185 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $1,879 | $89 |
| New patient visit (30+ min) | 17 | $1,553 | $91 |
| Short return visit | 11 | $561 | $37 |
2019: 7 services
| Short return visit (20+ min) | 66 | $6,622 | $64 |
| Biopsy of large bowel using a flexible endoscope | 36 | $5,269 | $146 |
| New patient visit (45+ min) | 35 | $4,614 | $132 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 40 | $4,209 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,370 | $177 |
| Return visit (30+ min) | 31 | $3,200 | $91 |
| New patient visit (30+ min) | 15 | $1,418 | $95 |
2018: 7 services
| Short return visit (20+ min) | 68 | $7,406 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $7,356 | $167 |
| Biopsy of large bowel using a flexible endoscope | 35 | $5,284 | $151 |
| New patient visit (45+ min) | 34 | $4,843 | $142 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 38 | $3,508 | $88 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,129 | $103 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 11 | $52 | $5 |
2017: 7 services
| Short return visit (20+ min) | 81 | $8,720 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,273 | $177 |
| New patient visit (45+ min) | 53 | $7,011 | $132 |
| Biopsy of large bowel using a flexible endoscope | 43 | $6,169 | $143 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 54 | $5,477 | $101 |
| Return visit (30+ min) | 24 | $2,612 | $97 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 12 | $2,544 | $212 |
2016: 9 services
| Short return visit (20+ min) | 77 | $8,262 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,763 | $178 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 43 | $4,876 | $111 |
| Biopsy of large bowel using a flexible endoscope | 32 | $4,366 | $136 |
| New patient visit (45+ min) | 18 | $2,722 | $151 |
| New patient visit (60+ min) | 12 | $2,300 | $192 |
| Return visit (30+ min) | 20 | $1,957 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,584 | $93 |
| New patient visit (30+ min) | 19 | $1,419 | $75 |
2015: 8 services
| Short return visit (20+ min) | 61 | $6,947 | $64 |
| New patient visit (45+ min) | 41 | $5,802 | $142 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 47 | $5,322 | $109 |
| Biopsy of large bowel using a flexible endoscope | 25 | $5,246 | $202 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,083 | $181 |
| Diagnostic exam of large bowel using a flexible endoscope | 15 | $2,744 | $183 |
| Return visit (30+ min) | 17 | $1,937 | $102 |
| New patient visit (30+ min) | 17 | $1,645 | $97 |
2014: 8 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $7,046 | $181 |
| New patient visit (45+ min) | 48 | $6,672 | $139 |
| Biopsy of large bowel using a flexible endoscope | 34 | $6,614 | $195 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 47 | $5,192 | $110 |
| Short return visit (20+ min) | 54 | $5,050 | $62 |
| Return visit (30+ min) | 24 | $2,894 | $93 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 11 | $2,668 | $243 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,865 | $64 |
2013: 7 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 53 | $9,804 | $175 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 39 | $4,895 | $126 |
| Biopsy of large bowel using a flexible endoscope | 20 | $4,249 | $212 |
| New patient visit (45+ min) | 31 | $4,234 | $137 |
| Short return visit (20+ min) | 31 | $3,087 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $2,491 | $62 |
| Return visit (30+ min) | 17 | $2,103 | $100 |
Drugs they prescribed that Part D paid
$124,502
Pharmacies billed $124,502 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 506) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
397 generic and 109 brand-name prescriptions · $124,502 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Creon | 25 | $91,444 | $3,658 |
| Mesalamine | 18 | $8,660 | $481 |
| Sod Sulf-Potass Sulf-Mag Sulf | 138 | $8,418 | $61 |
| Lubiprostone | 12 | $1,677 | $140 |
| Pantoprazole | 53 | $806 | $15 |
See all 9 drugs
| Creon | 25 | $91,444 | $3,658 |
| Mesalamine | 18 | $8,660 | $481 |
| Sod Sulf-Potass Sulf-Mag Sulf | 138 | $8,418 | $61 |
| Lubiprostone | 12 | $1,677 | $140 |
| Pantoprazole | 53 | $806 | $15 |
| Omeprazole | 121 | $668 | $6 |
| Esomeprazole Magnesium | 20 | $570 | $28 |
| Cholestyramine | 15 | $552 | $37 |
| Famotidine | 34 | $207 | $6 |
Year by year
| 2024 | 506 | 216 | 0% (0) | 22% | $124,502 |
| 2023 | 475 | 199 | 0% (0) | 24% | $54,419 |
| 2022 | 427 | 167 | 0% (0) | 30% | $71,995 |
| 2021 | 464 | 158 | 0% (0) | 34% | $93,469 |
| 2020 | 504 | 174 | 0% (0) | 32% | $113,250 |
| 2019 | 582 | 182 | 0% (0) | 31% | $190,044 |
| 2018 | 481 | 152 | 0% (0) | 39% | $212,681 |
| 2017 | 433 | 135 | 0% (0) | 38% | $179,223 |
| 2016 | 401 | 133 | 0% (0) | 40% | $155,426 |
| 2015 | 327 | 100 | 0% (0) | 47% | $290,466 |
| 2014 | 281 | 109 | 0% (0) | 47% | $27,344 |
| 2013 | 319 | 105 | 0% (0) | 44% | $39,877 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Sod Sulf-Potass Sulf-Mag Sulf | 114 | $8,745 | $77 |
| Mesalamine | 17 | $6,498 | $382 |
| Lubiprostone | 12 | $4,093 | $341 |
| Suprep | 12 | $1,439 | $120 |
| Pantoprazole | 68 | $1,196 | $18 |
| Dicyclomine | 17 | $732 | $43 |
| Omeprazole | 77 | $704 | $9 |
| Esomeprazole Magnesium | 15 | $666 | $44 |
| Famotidine | 39 | $489 | $13 |
| Loperamide | 12 | $446 | $37 |
| Nortriptyline | 12 | $85 | $7 |
2022: 10 drugs
| Mesalamine | 18 | $10,430 | $579 |
| Suprep | 85 | $9,782 | $115 |
| Sucralfate | 12 | $1,587 | $132 |
| Sod Sulf-Potass Sulf-Mag Sulf | 20 | $1,569 | $78 |
| Pantoprazole | 54 | $838 | $16 |
| Dicyclomine | 22 | $775 | $35 |
| Omeprazole | 76 | $476 | $6 |
| Esomeprazole Magnesium | 11 | $403 | $37 |
| Famotidine | 28 | $353 | $13 |
| Nortriptyline | 12 | $104 | $9 |
2021: 10 drugs
| Mesalamine | 29 | $21,946 | $757 |
| Suprep | 112 | $12,256 | $109 |
| Linzess | 14 | $7,453 | $532 |
| Sucralfate | 15 | $1,753 | $117 |
| Pantoprazole | 37 | $639 | $17 |
| Omeprazole | 72 | $582 | $8 |
| Famotidine | 38 | $453 | $12 |
| Dicyclomine | 28 | $422 | $15 |
| Prochlorperazine Maleate | 11 | $230 | $21 |
| Loperamide | 12 | $221 | $18 |
2020: 11 drugs
| Mesalamine | 40 | $32,130 | $803 |
| Suprep | 99 | $10,439 | $105 |
| Mesalamine Er | 11 | $9,644 | $877 |
| Budesonide Ec | 11 | $2,517 | $229 |
| Pantoprazole | 51 | $696 | $14 |
| Omeprazole | 86 | $619 | $7 |
| Dicyclomine | 35 | $592 | $17 |
| Famotidine | 22 | $487 | $22 |
| Loperamide | 12 | $279 | $23 |
| Prochlorperazine Maleate | 13 | $206 | $16 |
| Diphenoxylate-Atropine | 11 | $173 | $16 |
2019: 12 drugs
| Mesalamine | 36 | $29,157 | $810 |
| Suprep | 95 | $9,491 | $100 |
| Dexilant | 16 | $5,261 | $329 |
| Budesonide Ec | 13 | $3,794 | $292 |
| Cholestyramine | 12 | $1,929 | $161 |
| Pantoprazole | 50 | $860 | $17 |
| Omeprazole | 101 | $738 | $7 |
| Dicyclomine | 53 | $685 | $13 |
| Prochlorperazine Maleate | 13 | $355 | $27 |
| Loperamide | 11 | $351 | $32 |
| Ranitidine | 20 | $170 | $8 |
| Famotidine | 24 | $150 | $6 |
2018: 10 drugs
| Mesalamine | 40 | $35,577 | $889 |
| Budesonide Ec | 22 | $11,067 | $503 |
| Suprep | 73 | $6,765 | $93 |
| Cholestyramine | 15 | $1,891 | $126 |
| Omeprazole | 74 | $786 | $11 |
| Pantoprazole | 37 | $614 | $17 |
| Polyethylene Glycol 3350 | 18 | $325 | $18 |
| Famotidine | 21 | $193 | $9 |
| Dicyclomine | 16 | $133 | $8 |
| Ranitidine | 19 | $100 | $5 |
2017: 12 drugs
| Lialda | 27 | $29,194 | $1,081 |
| Mesalamine | 23 | $20,435 | $888 |
| Suprep | 66 | $5,828 | $88 |
| Linzess | 12 | $5,720 | $477 |
| Dexilant | 18 | $5,081 | $282 |
| Cholestyramine | 21 | $1,556 | $74 |
| Omeprazole | 94 | $856 | $9 |
| Pantoprazole | 28 | $366 | $13 |
| Polyethylene Glycol 3350 | 12 | $215 | $18 |
| Ranitidine | 22 | $133 | $6 |
| Nortriptyline | 11 | $72 | $7 |
| Dicyclomine | 11 | $66 | $6 |
2016: 11 drugs
| Lialda | 16 | $15,793 | $987 |
| Dexilant | 34 | $8,853 | $260 |
| Suprep | 69 | $5,736 | $83 |
| Apriso | 12 | $5,074 | $423 |
| Omeprazole | 86 | $778 | $9 |
| Polyethylene Glycol 3350 | 14 | $335 | $24 |
| Pantoprazole | 16 | $224 | $14 |
| Ranitidine | 19 | $117 | $6 |
| Famotidine | 12 | $116 | $10 |
| Nortriptyline | 13 | $94 | $7 |
| Dicyclomine | 12 | $89 | $7 |
2015: 8 drugs
| Dexilant | 38 | $8,215 | $216 |
| Asacol Hd | 11 | $6,133 | $558 |
| Suprep | 46 | $3,736 | $81 |
| Omeprazole | 59 | $720 | $12 |
| Pantoprazole | 23 | $346 | $15 |
| Diphenoxylate-Atropine | 14 | $313 | $22 |
| Famotidine | 14 | $233 | $17 |
| Dicyclomine | 14 | $97 | $7 |
2014: 9 drugs
| Asacol Hd | 15 | $7,506 | $500 |
| Dexilant | 33 | $6,255 | $190 |
| Nexium | 11 | $4,419 | $402 |
| Suprep | 53 | $4,079 | $77 |
| Carafate | 11 | $733 | $67 |
| Omeprazole | 45 | $590 | $13 |
| Pantoprazole | 26 | $481 | $19 |
| Imipramine | 12 | $103 | $9 |
| Dicyclomine | 11 | $57 | $5 |
2013: 7 drugs
| Asacol Hd | 22 | $10,042 | $456 |
| Suprep | 48 | $3,491 | $73 |
| Dexilant | 20 | $3,353 | $168 |
| Omeprazole | 54 | $767 | $14 |
| Pantoprazole | 52 | $764 | $15 |
| Dicyclomine | 13 | $221 | $17 |
| Famotidine | 11 | $157 | $14 |
Money from drug and device companies
$1,548 in 2025
| 2025 | 13 | 59 | None | $1,548 |
| 2024 | 9 | 49 | None | $1,214 |
| 2023 | 7 | 44 | None | $915 |
| 2022 | 6 | 22 | None | $436 |
| 2021 | 3 | 18 | None | $409 |
| 2020 | 7 | 18 | None | $394 |
| 2019 | 13 | 66 | None | $1,198 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Skyrizi | $546 | 19 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $235 | 9 payments
|
| Lilly USA | Omvoh | $148 | 5 payments
|
| Celltrion USA | Vegzelma | $142 | 7 payments
|
| Janssen Biotech | Tremfya | $127 | 5 payments
|
| Ardelyx | Ibsrela | $74 | 3 payments
|
See all 59 published payments
| Pfizer | Meals · 2025-12-18 | Velsipity | $24 |
| Celltrion USA | Meals · 2025-12-18 | Vegzelma | $18 |
| Abbvie | Meals · 2025-12-12 | Rinvoq | $23 |
| Novo Nordisk | Meals · 2025-12-05 | Wegovy | $18 |
| Abbvie | Meals · 2025-12-04 | Rinvoq | $21 |
| Ardelyx | Meals · 2025-11-21 | Ibsrela | $31 |
| Abbvie | Meals · 2025-11-19 | Rinvoq | $23 |
| Abbvie | Meals · 2025-11-12 | Skyrizi | $20 |
| Celltrion USA | Meals · 2025-11-08 | Vegzelma | $25 |
| Celltrion USA | Meals · 2025-11-06 | Vegzelma | $19 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-31 | Entyvio | $27 |
| Abbvie | Meals · 2025-10-30 | Skyrizi | $26 |
| Pfizer | Meals · 2025-10-24 | Velsipity | $22 |
| Braintree Laboratories | Meals · 2025-10-09 | Sutab | $28 |
| Abbvie | Meals · 2025-10-03 | Skyrizi | $23 |
| Abbvie | Meals · 2025-09-26 | Rinvoq | $23 |
| Lilly USA | Meals · 2025-09-16 | Omvoh | $20 |
| Ipsen Biopharmaceuticals | Meals · 2025-09-12 | Iqirvo | $23 |
| Abbvie | Meals · 2025-09-11 | Skyrizi | $133 |
| Abbvie | Meals · 2025-08-28 | Skyrizi | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-28 | Entyvio | $23 |
| Celltrion USA | Meals · 2025-08-20 | Vegzelma | $17 |
| Lilly USA | Meals · 2025-08-15 | Omvoh | $25 |
| Abbvie | Meals · 2025-08-15 | Rinvoq | $26 |
| QOL Medical | Meals · 2025-08-13 | Sucraid | $23 |
| Ardelyx | Meals · 2025-08-08 | Ibsrela | $22 |
| Abbvie | Meals · 2025-07-25 | Rinvoq | $21 |
| Abbvie | Meals · 2025-07-18 | Rinvoq | $18 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-07-02 | Entyvio | $39 |
| Celltrion USA | Meals · 2025-06-20 | Vegzelma | $22 |
| Lilly USA | Meals · 2025-06-06 | Omvoh | $35 |
| Abbvie | Meals · 2025-06-06 | Skyrizi | $33 |
| Abbvie | Meals · 2025-05-22 | Skyrizi | $20 |
| Ardelyx | Meals · 2025-05-09 | Ibsrela | $21 |
| Braintree Laboratories | Meals · 2025-05-08 | Sutab | $35 |
| Janssen Biotech | Meals · 2025-05-07 | Tremfya | $21 |
| Abbvie | Meals · 2025-04-25 | Rinvoq | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-24 | Entyvio | $27 |
| Janssen Biotech | Meals · 2025-04-23 | Tremfya | $25 |
| Abbvie | Meals · 2025-04-11 | Rinvoq | $29 |
| Aimmune Therapeutics | Meals · 2025-04-09 | Zenpep | $17 |
| Celltrion USA | Meals · 2025-03-28 | Vegzelma | $20 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-27 | Eohilia | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-26 | Entyvio | $26 |
| Celltrion USA | Meals · 2025-03-19 | Vegzelma | $22 |
| Pfizer | Meals · 2025-03-12 | Xeljanz | $16 |
| Lilly USA | Meals · 2025-03-11 | Omvoh | $35 |
| Janssen Biotech | Meals · 2025-03-07 | Tremfya | $26 |
| Medtronic | Meals · 2025-03-05 | Gi Genius | $46 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-28 | Entyvio | $9 |
| Aimmune Therapeutics | Meals · 2025-02-14 | Zenpep | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-07 | Eohilia | $38 |
| Janssen Biotech | Meals · 2025-02-05 | Tremfya | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-31 | Entyvio | $22 |
| Janssen Biotech | Meals · 2025-01-24 | Tremfya | $30 |
| Abbvie | Meals · 2025-01-16 | Skyrizi | $3 |
| Abbvie | Meals · 2025-01-16 | Rinvoq | $29 |
| Abbvie | Meals · 2025-01-15 | Rinvoq | $27 |
| Lilly USA | Meals · 2025-01-08 | Omvoh | $34 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,214
| Abbvie | Rinvoq | $376 | 17 payments
|
| Janssen Biotech | Stelara | $268 | 9 payments
|
| Lilly USA | Omvoh | $210 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $143 | 6 payments
|
| Pfizer | Xeljanz | $90 | 4 payments
|
| Phathom Pharmaceuticals | Voquezna | $45 | 2 payments
|
| Celltrion USA | Vegzelma | $43 | 2 payments
|
| Ipsen Biopharmaceuticals | Iqirvo | $25 | 1 payment
|
| Celgene | Zeposia | $15 | 1 payment
|
2023: $915
| AbbVie | Rinvoq | $443 | 20 payments
|
| Janssen Biotech | Stelara | $178 | 9 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $125 | 7 payments
|
| Pfizer | Xeljanz | $70 | 3 payments
|
| Celltrion USA | Yuflyma | $43 | 2 payments
|
| QOL Medical | Sucraid | $38 | 2 payments
|
| Nestle Healthcare Nutrition | Zenpep | $19 | 1 payment
|
2022: $436
| Abbvie | Skyrizi | $186 | 10 payments
|
| Janssen Biotech | Stelara | $90 | 4 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $56 | 3 payments
|
| QOL Medical | Sucraid | $43 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $35 | 2 payments
|
| Pfizer | Xeljanz | $24 | 1 payment
|
2021: $409
| AbbVie | Humira | $311 | 13 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $56 | 3 payments
|
| RedHill Biopharma | Talicia | $42 | 2 payments
|
2020: $394
| AbbVie | Humira | $144 | 7 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $60 | 3 payments
|
| Janssen Biotech | Stelara | $53 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $46 | 2 payments
|
| Pfizer | Inflectra | $41 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $27 | 1 payment
|
| Gilead Sciences | None | $24 | 1 payment
|
2019: $1,198
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $271 | 18 payments
|
| Pfizer | Inflectra | $252 | 13 payments
|
| AbbVie | Humira | $211 | 10 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $132 | 7 payments
|
| Gilead Sciences | None | $110 | 5 payments
|
| Ferring Pharmaceuticals | Clenpiq | $64 | 4 payments
|
| Janssen Biotech | Stelara | $52 | 2 payments
|
| Braintree Laboratories | Motofen | $35 | 2 payments
|
| QOL Medical | Sucraid | $19 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $17 | 1 payment
|
| Shire North American Group | Gattex | $13 | 1 payment
|
| Concordia Pharmaceuticals | Donnatal | $11 | 1 payment
|
| Napo Pharmaceuticals | Mytesi | $11 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 84.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1275704744
- Licence
- CA A95509California A95509: Current · expires 2027-12-31
- Trained
- Loma Linda University School of Medicine, 2004 · 22 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 2186 Geary Blvd, Suite #320, San Francisco, CA, 94115
- NPI first listed
- 2008-03-12
- NPI last updated
- 2013-02-08
This is when the NPI record was last certified, not a medical board exam.